sur Sandoz Group AG (isin : CH1243598427)
Sandoz Launches Afqlir® in Europe for Retinal Diseases
Sandoz Group AG has announced the European debut of Afqlir® (aflibercept), a cost-effective treatment for retinal diseases, after receiving European Commission approval in November 2024. This biosimilar matches the reference medicine, Eylea®, in effectiveness and safety, offering a crucial alternative for conditions such as neovascular age-related macular degeneration (nAMD).
This launch aligns with Sandoz's strategy to expand its biosimilar portfolio, which already includes Tyruko® in the US and the anticipated launch of denosumab biosimilars in Europe. By entering the USD 15 billion anti-VEGF market, Sandoz continues to enhance its presence in ophthalmology.
Afqlir® has commenced its rollout in the UK, with plans to expand to major European markets. This move signifies a step towards providing more sustainable healthcare solutions, addressing the growing burden of retinal diseases.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Sandoz Group AG